

Appendix Table 1. Recommendations by American Diabetes Association, American Heart Association, and American Stroke Association for preventing stroke in people with diabetes

Well-controlled HbA1c	Well-controlled glycemic level was considered an HbA1c level less than a target level. For each participant, we defined an individualized HbA1c level target between 7.0% and 8.0%, depending on the participant's age and presence of stroke history. For participants aged 45-64 years, the target HbA1c level was <7.0% in the absence of stroke history or <8.0% in the presence of stroke history. For participants aged ≥65 years, the target HbA1c level was <7.5% in those without stroke history or <8.0% in those with stroke history.
Well-controlled blood pressure (BP)	Well-controlled BP level was defined as a systolic/diastolic BP level <140/90 mmHg.
Statin therapy	Moderate- or high-intensity statin therapy should be used for all patients with diabetes aged ≥40 years. All individuals in our study cohort with T2D aged ≥45 years met this criterion for the statin treatment.
Treatment with aspirin or clopidogrel	The use of aspirin or clopidogrel (as an alternative for aspirin allergy) for atherosclerotic cardiovascular disease (ASCVD) prophylaxis is reasonable for people whose risk is sufficiently high (10-year ASCVD risk >10%) for the benefits to outweigh the risks associated with treatment.
Non-smoking	All patients should be advised for smoking cessation to avoid using cigarettes and other tobacco products.
Well-controlled body mass index (BMI)	Lifestyle intervention, pharmacotherapy, or other treatment approaches were recommended for diabetes patients with overweight or obesity (BMI ≥25 kg/m ²). Well-controlled BMI was defined as a BMI less than 25.
Treatment with angiotensin converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB)	Pharmacological therapy for diabetes patients with and hypertension should comprise a regimen that includes either an ACE inhibitor or ARB.
	An ACE inhibitor or ARB, indicated for hypertension treatment, is recommended for diabetes patients with hypertension and albuminuria.

Appendix Table 2. Characteristics (weighted) of US adults with type 2 diabetes by stroke history (NHANES 2001-2018)

Characteristics ¹	T2D without stroke history (95% CI)	T2D with stroke history (95% CI)
Sample size (unweighted)	4,300	534
Age, year	63.4 (62.9, 63.8)	68.2 (67.1, 69.4)
Male, %	51.1 (49.0, 53.3)	48.2 (42.8, 53.6)
Race, %		
Mexican American	8.6 (6.8, 10.3)	5.9 (4.0, 7.8)
Other Hispanic	5.3 (4.3, 6.3)	2.5 (1.5, 3.6)
Non-Hispanic white	62.5 (59.4, 65.6)	66.5 (61.9, 71.0)
Non-Hispanic black	14.8 (12.9, 16.7)	16.3 (13.2, 19.4)
Other races	8.8 (7.5, 10.2)	8.8 (5.8, 11.7)
Uninsured, %	8.1 (7.0, 9.2)	5.2 (2.7, 7.6)
Diabetes duration, year	9.9 (9.6, 10.3)	12.6 (11.5, 13.7)
<5 years, %	30.9 (29.0, 32.8)	24.6 (20.1, 29.0)
5-10 years, %	25.0 (23.0, 26.9)	24.0 (19.0, 29.0)
>10 years, %	44.1 (41.9, 46.4)	51.4 (46.0, 56.9)
Anti-diabetic agents, %		
Insulin use	20.2 (18.6, 21.9)	29.4 (24.2, 34.6)
OAD use	77.8 (76.0, 79.6)	67.1 (62.1, 72.1)
Insulin/OAD use	85.2 (83.7, 86.7)	80.5 (76.0, 85.1)
HbA1c, %	7.2 (7.2, 7.3)	7.1 (6.9, 7.3)
≥9%, %	12.4 (11.0, 13.9)	11.7 (7.4, 15.9)
<8%, %	76.9 (75.0, 78.8)	79.9 (74.9, 84.9)
<7%, %	53.7 (51.1, 56.3)	59.8 (53.7, 65.9)
SBP, mmHg	130.7 (129.8, 131.6)	134.1 (131.6, 136.6)
DBP, mmHg	68.0 (67.3, 68.7)	65.8 (64.4, 67.3)
TC, mg/dL	182.8 (180.3, 185.4)	180.6 (175.3, 185.9)
LDL, mg/dL	100.4 (97.9, 102.9)	101.0 (94.1, 107.9)
HDL, mg/dL	47.6 (47.0, 48.2)	46.8 (45.5, 48.1)
Lipid ratio (TC/HDL)	4.1 (4.0, 4.2)	4.1 (3.9, 4.3)
BMI, kg/m ²	32.5 (32.1, 32.9)	32.5 (31.8, 33.3)
UACR, mg/g	124.3 (105.4, 143.2)	201.9 (146.8, 257.0)
UACR, ² mg/g	18.7 (17.5, 19.9)	30.3 (25.3, 35.9)
UACR ≥30 mg/g, %	28.3 (26.3, 30.2)	42.3 (36.7, 48.0)
HTN, %	76.2 (74.1, 78.9)	88.1 (84.5, 91.7)
HTN and UACR ≥30 mg/g, %	23.7 (21.8, 25.5)	38.1 (32.5, 43.7)
10-year ASCVD risk >10%, %	72.8 (70.7, 75.1)	88.6 (85.1, 92.2)

Abbreviations: T2D, type 2 diabetes; NHANES, National Health and Nutrition Examination Survey; CI, confidence interval; OAD, oral anti-diabetic drug; SBP, systolic blood pressure; DBP, diastolic blood pressure; TC, total cholesterol; LDL, low-density lipoprotein; HDL, high-density lipoprotein; BMI, body mass index; UACR, urine albumin-to-creatinine ratio; HTN, hypertension; ASCVD, atherosclerotic cardiovascular disease.

¹Categorical variables were presented as percentage (95% CI) and continuous variables were presented as mean (95% CI) unless otherwise stated. Diabetes duration was calculated as the age at survey minus the self-reported diabetes-diagnosed age. The LDL data were estimated from NHANES 2001-2016 because the LDL data in NHANES 2017-2018 were unavailable at the time of performing the analyses.

²The UACR data were reported as the geometric mean (95% CI).

Appendix Table 3. Characteristics (weighted) of US adults with type 2 diabetes and without stroke history from NHANES 2001-2018

Characteristics ¹	2001-2002 (N=330)	2003-2004 (N=364)	2005-2006 (N=330)	2007-2008 (N=522)	2009-2010 (N=534)	2011-2012 (N=482)	2013-2014 (N=509)	2015-2016 (N=592)	2017-2018 (N=637)
Age, year	63.7 (61.2-66.2)	63.0 (61.1-64.9)	62.8 (61.4-64.1)	63.0 (62.0-64.0)	63.3 (61.8-64.7)	63.3 (62.1-64.4)	62.8 (61.7-63.8)	63.6 (62.3-64.9)	64.4 (62.9-65.8)
Male, %	49.4 (42.9-56.0)	46.8 (40.4-53.2)	46.8 (39.2-54.4)	50.0 (42.6-57.5)	50.3 (44.6-56.0)	50.0 (44.0-56.0)	49.8 (43.4-56.3)	56.9 (50.6-63.2)	54.1 (46.4-61.7)
Race, %									
Mexican American	6.9 (3.5-10.3)	7.2 (0.9-13.4)	8.4 (4.9-11.9)	8.0 (2.46-13.6)	9.2 (2.5-15.9)	7.5 (2.5-12.5)	9.2 (2.9-15.5)	10.0 (3.8-16.3)	8.8 (5.1-12.6)
Other Hispanic	6.4 (0-13.1)	2.9 (0-6.0)	5.2 (0.7-9.7)	4.8 (1.4-8.3)	5.3 (2.5-8.0)	5.8 (2.0-9.7)	5.1 (3.0-7.2)	6.2 (3.3-9.2)	5.4 (3.0-7.9)
Non-Hispanic white	66.2 (57.2-75.1)	71.1 (61.4-80.8)	63.7 (54.2-73.2)	62.8 (19.2-76.2)	58.1 (49.1-67.1)	61.6 (50.8-72.5)	62.0 (52.2-71.7)	61.2 (51.6-70.9)	60.8 (54.4-67.2)
Non-Hispanic black	13.6 (6.3-20.9)	14.4 (8.5-20.4)	16.6 (10.2-22.9)	17.3 (9.6-25.0)	16.8 (12.3-21.2)	16.2 (7.6-24.7)	15.4 (10.8-19.9)	13.6 (7.8-19.3)	11.2 (7.0-15.4)
Other race	6.9 (2.0-11.7)	4.4 (1.5-7.3)	6.14 (3.4-8.9)	7.1 (2.1-12.0)	10.6 (5.8-15.5)	8.9 (4.7-13.1)	8.3 (4.8-11.9)	9.0 (4.6-13.3)	13.7 (9.1-18.2)
Uninsured, %	7.1 (3.7-10.4)	9.1 (4.4-13.7)	7.6 (3.6-11.6)	10.4 (6.7-14.1)	9.1 (5.4-12.7)	11.5 (7.8-15.3)	8.4 (4.8-12.0)	5.1 (3.9-6.4)	6.4 (2.9-9.9)
Diabetes duration, year	9.3 (7.8-10.8)	9.0 (7.9-10.0)	9.3 (8.2-10.3)	9.5 (8.9-10.1)	9.4 (8.3-10.4)	9.4 (8.2-10.5)	10.4 (9.6-11.2)	10.7 (9.4-12.0)	11.2 (10.1-12.2)
<5 years, %	37.9 (30.7-45.0)	37.1 (28.5-45.6)	30.6 (24.6-36.7)	28.8 (23.3-34.3)	36.0 (29.3-42.7)	35.4 (29.2-41.6)	24.8 (20.1-29.6)	28.4 (23.8-33.1)	26.7 (20.4-33.0)
5-10 years, %	23.2 (16.6-30.0)	23.5 (18.5-28.6)	27.9 (21.0-34.8)	29.5 (23.2-35.8)	21.8 (17.3-26.3)	22.3 (18.7-25.8)	27.4 (22.3-32.5)	24.3 (19.3-29.2)	24.8 (16.3-33.4)
>10 years, %	38.9 (31.6-46.2)	39.4 (32.8-45.9)	41.5 (33.2-49.7)	41.7 (36.6-46.9)	42.2 (37.2-47.3)	42.4 (35.0-49.7)	47.8 (40.3-55.2)	47.3 (40.4-54.2)	48.5 (40.4-56.6)
Anti-diabetic agents, %									
Insulin use	19.1 (10.8-27.4)	18.4 (13.6-23.3)	20.5 (13.5-27.5)	21.9 (16.1-27.7)	20.7 (16.9-24.4)	21.6 (15.0-28.3)	19.8 (15.9-23.8)	21.7 (17.1-26.2)	18.1 (13.9-22.4)
OAD use	71.5 (65.3-77.7)	74.3 (67.8-80.8)	76.7 (68.9-84.4)	79.2 (72.1-86.3)	80.0 (73.5-83.1)	81.1 (73.8-88.3)	75.3 (71.6-79.1)	79.2 (76.0-82.4)	79.0 (74.2-83.8)
Insulin/OAD use	84.6 (80.0-89.2)	81.4 (75.4-87.4)	83.3 (76.8-89.9)	88.2 (83.0-93.4)	88.3 (83.2-93.4)	86.0 (80.3-91.7)	83.5 (79.9-87.1)	14.0 (10.5-17.5)	84.4 (79.9-88.9)
HbA1c, %	7.4 (7.0-7.7)	7.2 (6.9-7.4)	7.0 (6.9-7.2)	7.2 (7.0-7.3)	7.1 (6.9-7.3)	7.2 (7.0-7.4)	7.4 (7.3-7.5)	7.3 (7.0-7.6)	7.3 (7.1-7.4)
≥9%, %	16.2 (9.5-23.0)	12.7 (8.7-16.6)	9.4 (4.7-14.0)	12.5 (8.3-16.6)	8.8 (6.2-11.4)	12.0 (9.4-14.6)	15.2 (11.0-19.4)	13.6 (7.9-19.4)	11.8 (7.9-15.6)
<8%, %	74.8 (67.6-82.0)	78.4 (73.4-83.4)	82.8 (77.3-88.3)	77.8 (73.0-82.6)	84.0 (78.7-89.3)	74.2 (66.8-81.6)	70.1 (65.0-75.3)	75.5 (68.5-82.5)	77.7 (73.3-82.0)
<7%, %	53.0 (46.5-59.4)	59.0 (51.5-66.5)	57.2 (47.5-66.9)	55.1 (48.7-61.5)	55.3 (46.5-64.2)	57.8 (51.5-64.0)	49.6 (43.1-56.0)	50.5 (41.6-59.4)	51.0 (41.9-60.2)
SBP, mmHg	131.3 (127.9-134.7)	132.2 (128.5-136.0)	131.6 (128.1-135.0)	131.4 (128.2-135.0)	127.4 (124.1-130.6)	130.4 (128.4-132.5)	131.7 (128.7-134.7)	128.9 (126.6-131.2)	132.0 (129.4-134.6)
DBP, mmHg	68.8 (66.0-71.5)	67.6 (65.0-70.2)	68.5 (65.9-71.1)	67.9 (64.6-70.1)	65.5 (63.5-67.6)	66.9 (65.2-68.7)	69.3 (67.4-71.1)	67.2 (65.8-68.7)	70.1 (68.1-72.2)
TC, mg/dL	207.1 (190.0-224.2)	202.0 (194.9-209.0)	189.1 (180.5-197.7)	179.1 (172.1-186.1)	182.8 (178.7-186.9)	177.0 (171.2-182.9)	176.7 (170.2-183.1)	177.1 (169.8-184.5)	177.0 (168.6-185.4)
LDL, mg/dL	113.3 (108.5-118.2)	109.9 (96.4-123.3)	102.0 (94.8-109.2)	92.5 (85.8-99.3)	103.7 (99.5-107.9)	96.2 (88.4-104.0)	98.3 (93.7-102.9)	97.6 (91.2-103.9)	
HDL, mg/dL	46.6 (45.1-48.2)	49.4 (47.4-51.5)	52.5 (49.6-55.3)	46.4 (44.8-48.0)	47.3 (45.7-49.0)	46.1 (44.0-48.2)	47.0 (45.1-48.9)	47.8 (45.4-50.2)	46.8 (45.9-47.7)
Lipid ratio (TC/HDL)	4.7 (4.3-5.1)	4.4 (4.2-4.6)	3.8 (3.6-4.0)	4.2 (4.0-4.3)	4.2 (4.0-4.4)	4.1 (3.8-4.3)	4.0 (3.7-4.3)	4.0 (3.8-4.3)	4.0 (3.8-4.3)
BMI, kg/m ²	30.6 (29.5-31.7)	31.9 (30.5-33.3)	31.7 (30.6-32.9)	32.8 (31.8-33.8)	33.1 (32.0-34.3)	32.9 (31.4-34.3)	32.7 (31.6-33.7)	32.4 (31.5-33.2)	33.0 (31.6-34.4)
UACR, mg/g	139.8 (83.2-196.3)	74.1 (33.8-114.4)	104.3 (58.5-150.1)	203.0 (90.7-315.3)	94.5 (57.6-131.5)	107.3 (67.2-147.4)	203.6 (144.9-262.2)	78.2 (34.1-122.3)	120.2 (62.1-178.4)
UACR, ² mg/g	21.1 (16.6-26.6)	16.8 (13.9-20.1)	17.8 (14.7-21.5)	21.8 (18.7-25.5)	16.6 (13.7-20.1)	16.8 (14.2-20.1)	20.5 (18.2-23.3)	16.6 (13.2-21.1)	21.1 (17.1-26.0)
UACR ≥30 mg/g, %	35.2 (28.5-42.0)	28.0 (21.1-34.8)	27.7 (22.2-33.3)	31.7 (27.7-35.8)	26.3 (20.3-32.2)	24.8 (19.2-30.0)	28.5 (22.5-34.5)	23.3 (16.9-29.7)	32.4 (26.9-38.0)
HTN, %	71.8 (63.9-79.7)	75.3 (68.0-82.7)	71.4 (66.0-76.8)	72.3 (66.0-78.9)	80.3 (72.0-88.5)	77.2 (71.6-82.8)	77.8 (73.3-82.3)	73.9 (65.7-82.0)	80.6 (75.6-85.7)
HTN and UACR ≥30 mg/g, %	24.5 (18.1-30.9)	22.6 (17.7-27.5)	21.3 (16.0-26.2)	25.3 (21.0-29.5)	21.0 (15.2-26.7)	22.2 (16.8-27.7)	25.0 (19.7-30.3)	20.1 (13.5-26.7)	29.5 (24.0-35.0)
10-year ASCVD risk >10%, %	74.7 (66.6-82.9)	77.1 (69.0-85.2)	67.6 (62.4-72.8)	73.3 (68.1-78.4)	71.2 (65.4-76.9)	69.8 (62.5-77.1)	67.9 (59.5-76.2)	77.1 (71.7-82.5)	76.2 (69.5-83.0)

Abbreviations: T2D, type 2 diabetes; NHANES, National Health and Nutrition Examination Survey; CI, confidence interval; OAD, oral anti-diabetic drug; SBP, systolic blood pressure; DBP, diastolic blood pressure; TC, total cholesterol; LDL, low-density lipoprotein; HDL, high-density lipoprotein; BMI, body mass index; UACR, urine albumin-to-creatinine ratio; HTN, hypertension; ASCVD, atherosclerotic cardiovascular disease.

¹Categorical variables were presented as percentage (95% CI) and continuous variables were presented as mean (95% CI) unless otherwise stated. Diabetes duration was calculated as the age reported during the survey interview minus the self-reported diabetes-diagnosed age. The LDL data were estimated from NHANES 2001-2016 because the LDL data in NHANES 2017-2018 were unavailable at the time of performing the analyses.

²The UACR data were reported as the geometric mean (95% CI).

Appendix Table 4. Characteristics (weighted) of US adults with type 2 diabetes and with stroke history from NHANES 2001-2018

Characteristics ¹	2001-2002 (N=36)	2003-2004 (N=50)	2005-2006 (N=54)	2007-2008 (N=75)	2009-2010 (N=63)	2011-2012 (N=57)	2013-2014 (N=58)	2015-2016 (N=60)	2017-2018 (N=81)
Age, year	68.3 (65.1-71.5)	66.3 (61.3-71.4)	68.3 (66.7-69.8)	65.8 (62.2-69.3)	67.9 (63.6-72.3)	71.1 (68.1-74.1)	68.7 (63.3-74.1)	68.9 (65.0-72.9)	68.8 (66.8-70.7)
Male, %	38.2 (19.8-56.7)	41.9 (28.4-55.5)	38.0 (22.9-53.2)	37.3 (21.1-53.5)	55.9 (42.8-69.0)	55.5 (34.7-76.2)	48.2 (31.0-65.4)	60.9 (45.7-76.2)	51.9 (34.5-69.3)
Race, %									
Mexican American	3.6 (1.2-5.9)	7.7 (0.6-14.8)	4.56 (0-10.3)	4.8 (2.6-7.1)	7.9 (0-16.6)	6.3 (0-15.9)	7.6 (1.1-14.1)	8.7 (1.0-16.4)	2.8 (0.0-6.6)
Other Hispanic	2.9 (0-10)	0	1.2 (0-3.5)	1.8 (0-4.3)	2.8 (1.3-4.2)	3.9 (0-8.6)	3.5 (0-6.9)	3.3 (1.7-4.8)	3.0 (0.0-7.2)
Non-Hispanic white	67.9 (53.6-82.1)	63.9 (47.9-79.8)	74.2 (59.3-89.1)	66.9 (55.2-78.6)	67.8 (55.6-80.0)	46.0 (31.7-60.2)	73.4 (61.3-85.6)	61.8 (43.1-80.5)	71.4 (58.7-84.0)
Non-Hispanic black	25.7 (14.9-36.4)	14.3 (6.8-21.8)	20.0 (8.4-31.6)	20.4 (10.5-30.2)	14.4 (5.7-23.1)	22.6 (5.9-39.2)	11.5 (3.4-19.6)	9.0 (2.1-15.9)	15.5 (6.5-24.4)
Other race	0	14.1 (9.1-19.1)	0	6.0 (0-13.6)	7.2 (1.8-12.6)	21.2 (3.1-39.3)	4.0 (0-9.1)	17.2 (0.8-33.6)	7.4 (4.0-10.8)
Uninsured, %	3.4 (2.3-4.4)	12.4 (0-33.3)	8.23 (0-18.3)	8.0 (1.7-14.4)	3.6 (0-7.5)	4.7 (0.8-8.5)	2.4 (0-6.1)	3.2 (0.1-6.3)	2.2 (0-4.8)
Diabetes duration, year	13.3 (6.8-19.7)	9.7 (6.2-13.2)	11.3 (8.7-14.0)	10.6 (7.8-13.4)	10.8 (8.8-12.7)	17.1 (13.3-21.0)	13.0 (10.3-15.8)	13.4 (8.1-18.7)	13.7 (10.2-17.2)
<5 years, %	26.8 (14.9-38.7)	22.7 (13.7-31.7)	33.1 (16.7-49.5)	35.3 (24.3-46.3)	31.4 (19.8-43.1)	13.1 (5.5-20.8)	20.3 (2.1-38.5)	27.4 (4.0-50.7)	14.7 (6.7-22.7)
5-10 years, %	29.5 (6.5-52.6)	53.2 (38.0-68.3)	15.4 (0-30.8)	19.7 (8.5-31.0)	16.8 (4.2-29.5)	9.4 (1.1-17.7)	28.8 (14.4-43.1)	21.6 (1.2-42.0)	26.1 (9.9-42.4)
>10 years, %	43.7 (22.4-64.9)	24.2 (10.8-37.6)	51.5 (29.9-73.1)	45.0 (32.5-57.5)	51.7 (40.3-63.1)	77.5 (67.8-87.1)	50.9 (35.3-66.5)	51.1 (31.1-71.1)	59.2 (39.8-78.5)
Anti-diabetic agents, %									
Insulin use	33.3 (14.5-52.1)	12.3 (0-27.0)	27.1 (18.1-36.0)	34.0 (19.2-48.8)	31.0 (14.6-47.5)	37.2 (11.9-62.4)	36.7 (17.8-55.5)	23.5 (7.1-39.9)	28.7 (16.0-41.4)
OAD use	71.5 (53.1-89.9)	64.8 (37.7-91.9)	57.0 (48.3-65.7)	75.1 (59.5-90.7)	79.9 (69.5-90.3)	71.5 (51.8-91.2)	54.4 (40.9-68.0)	65.6 (46.5-84.7)	68.4 (56.3-80.5)
Insulin/OAD use	86.4 (74.8-97.9)	71.8 (44.0-99.7)	77.2 (63.2-91.3)	92.6 (86.6-98.5)	89.0 (78.8-99.3)	82.8 (70.0-95.6)	76.4 (61.9-91.0)	74.7 (55.5-93.8)	77.5 (68.6-86.4)
HbA1c, %	7.5 (6.7-8.4)	6.9 (6.0-7.9)	6.7 (6.1-7.3)	7.2 (6.7-7.6)	6.9 (6.6-7.3)	7.8 (7.1-8.4)	7.1 (5.8-8.4)	7.1 (6.5-7.6)	7.0 (6.6-7.3)
≥9%, %	19.3 (0-43.5)	5.8 (0-13.7)	14.0 (0.7-27.2)	9.1 (0-20.7)	6.7 (0-11.7)	22.4 (2.4-42.5)	18.0 (0-39.0)	9.2 (1.3-17.1)	6.2 (0.3-12.2)
<8%, %	75.7 (50.1-100)	87.1 (73.2-100)	83.6 (70.8-96.3)	76.1 (63.9-88.4)	83.0 (68.3-97.8)	63.5 (44.8-82.2)	76.1 (51.8-100)	81.3 (69.4-93.3)	89.0 (79.6-98.3)
<7%, %	56.1 (29.0-83.1)	73.6 (52.0-95.2)	72.0 (56.8-87.1)	53.0 (45.4-60.7)	65.2 (52.2-78.1)	37.9 (17.8-58.1)	68.5 (41.5-95.4)	50.1 (29.0-71.1)	61.3 (45.7-77.0)
SBP, mmHg	145.7 (138.2-153.3)	135.8 (127.0-144.6)	137.1 (132.1-142.1)	134.7 (129.3-140.0)	127.6 (120.9-134.3)	128.0 (122.3-133.6)	125.2 (115.7-134.7)	133.1 (122.5-143.7)	142.5 (134.0-151.1)
DBP, mmHg	70.7 (65.3-76.0)	65.1 (55.7-74.5)	61.0 (57.0-65.0)	68.5 (62.8-74.2)	61.0 (56.5-65.4)	63.9 (58.9-68.8)	63.4 (59.7-67.0)	62.9 (59.5-66.3)	74.2 (71.1-77.3)
TC, mg/dL	198.6 (165.7-231.4)	208.8 (196.4-221.2)	188.4 (163.5-213.3)	190.8 (175.9-205.8)	170.6 (156.0-185.2)	181.2 (156.4-206.0)	169.4 (152.9-185.8)	167.4 (157.7-177.1)	169.4 (161.9-176.8)
LDL, mg/dL	108.8 (NA)	125.0 (85.5-164.4)	106.0 (81.8-130.2)	96.7 (83.0-110.4)	92.9 (70.8-114.9)	103.2 (65.1-141.3)	104.0 (95.0-123.1)	78.7 (63.3-94.1)	
HDL, mg/dL	43.6 (40.7-46.4)	46.3 (41.8-50.8)	52.2 (48.2-56.3)	43.7 (39.4-48.0)	45.9 (40.7-51.1)	47.1 (42.2-51.9)	46.0 (42.8-49.1)	46.4 (42.5-50.3)	48.5 (43.8-53.2)
Lipid ratio (TC/HDL)	4.7 (4.0-5.3)	4.7 (4.3-5.2)	3.8 (3.3-4.4)	4.8 (3.8-5.7)	4.0 (3.7-4.3)	4.1 (3.5-4.7)	3.8 (3.5-4.1)	3.9 (3.5-4.2)	3.7 (3.3-4.1)
BMI, kg/m ²	32.6 (29.1-36.0)	31.6 (27.6-35.5)	31.7 (30.3-33.1)	33.3 (31.4-35.2)	34.0 (31.9-36.2)	32.7 (29.1-36.3)	32.1 (30.5-33.6)	33.0 (29.9-36.2)	31.9 (30.3-33.6)
UACR, mg/g	215.1 (-169.0-599.2)	231.8 (-30.5-494.2)	485.4 (242.8-728.1)	213.6 (0.8-426.4)	65.8 (-7.9-139.6)	147.5 (-4.28-299.2)	161.8 (20.9-302.7)	212.5 (36.9-388.2)	126.3 (13.8-238.9)
UACR, ² mg/g	38.5 (15.0-98.5)	33.4 (16.4-67.4)	36.2 (20.7-62.8)	48.9 (29.4-80.6)	16.4 (10.6-25.3)	28.5 (15.2-53.5)	28.2 (15.5-51.4)	29.7 (12.8-68.0)	25.5 (17.5-37.7)
UACR ≥30 mg/g, %	41.4 (21.1-61.7)	42.0 (19.3-64.7)	39.3 (23.2-55.4)	63.3 (53.6-73.1)	22.4 (5.9-38.9)	56.6 (44.1-69.1)	38.9 (15.4-62.4)	40.9 (18.9-62.9)	35.2 (20.8-49.5)
HTN, %	93.8 (81.8-100.0)	97.4 (94.5-100.0)	86.0 (72.4-99.6)	96.1 (92.9-99.3)	74.9 (61.0-88.7)	92.6 (84.3-100.0)	82.2 (76.0-88.5)	81.1 (61.7-100.0)	92.1 (83.4-100.0)
HTN and UACR ≥30 mg/g, %	41.8 (16.6-67.1)	36.6 (13.6-57.8)	35.9 (18.4-53.4)	58.7 (47.3-70.2)	21.6 (4.4-38.8)	52.0 (38.9-65.1)	25.9 (5.8-46.0)	38.2 (15.5-61.0)	32.3 (18.8-45.9)
10-year ASCVD risk >10%, %	94.2 (92.2-96.1)	93.2 (80.3-100.0)	87.4 (76.6-98.2)	88.0 (81.6-94.4)	82.0 (71.2-92.8)	94.2 (87.3-100.0)	87.3 (79.1-95.6)	87.3 (68.3-100.0)	88.5 (76.9-100.0)

Abbreviations: T2D, type 2 diabetes; NHANES, National Health and Nutrition Examination Survey; CI, confidence interval; OAD, oral anti-diabetic drug; SBP, systolic blood pressure; DBP, diastolic blood pressure; TC, total cholesterol; LDL, low-density lipoprotein; HDL, high-density lipoprotein; BMI, body mass index; UACR, urine albumin-to-creatinine ratio; HTN, hypertension; ASCVD, atherosclerotic cardiovascular disease.

¹Categorical variables were presented as percentage (95% CI) and continuous variables were presented as mean (95% CI) unless otherwise stated. Diabetes duration was calculated as the age reported during the survey interview minus the self-reported diabetes-diagnosed age. The LDL data were estimated from NHANES 2001-2016 because the LDL data in NHANES 2017-2018 were unavailable at the time of performing the analyses.

²The UACR data were reported as the geometric mean (95% CI).